Bionomics Ltd
ASX:BNO
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Bionomics Ltd
Net Income (Common)
Bionomics Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Bionomics Ltd
ASX:BNO
|
Net Income (Common)
-AU$24.9m
|
CAGR 3-Years
-62%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-21%
|
|
|
Opthea Ltd
ASX:OPT
|
Net Income (Common)
-$162.8m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-71%
|
CAGR 10-Years
-41%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Net Income (Common)
-$102.1m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-1%
|
|
|
CSL Ltd
ASX:CSL
|
Net Income (Common)
$3B
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
8%
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Net Income (Common)
AU$32.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Net Income (Common)
-AU$50.3m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
-33%
|
|
Bionomics Ltd
Glance View
Bionomics Ltd. is a clinical stage biopharmaceutical company. The firm is engaged in discovery and development of novel drug candidates focused on the treatment of central nervous system disorders. The firm's segment includes Drug discovery and development and Contract services. Drug discovery and development segment includes discovery, development, and commercialization of compounds to match a target product profile. Contract services segment includes provision of scientific services on a fee for service basis to both external and internal customers. Its product candidates include BNC210, BNC375, BNC101 and BNC105. The BNC210 provides treatment for anxiety disorders, co-morbid anxiety, and depression. The BNC375 is a molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease (AD).The Company operates in three geographical areas, such as Australia, France and United States of America.
See Also
What is Bionomics Ltd's Net Income (Common)?
Net Income (Common)
-24.9m
AUD
Based on the financial report for Dec 31, 2022, Bionomics Ltd's Net Income (Common) amounts to -24.9m AUD.
What is Bionomics Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-21%
Over the last year, the Net Income (Common) growth was -15%. The average annual Net Income (Common) growth rates for Bionomics Ltd have been -62% over the past three years , -33% over the past five years , and -21% over the past ten years .